Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Arctic Vision Completes China Phase III Enrollment for Macular Edema Candidate

publication date: Oct 4, 2023

Arctic Vision, a Shanghai ophthalmology biopharma, has completed enrollment in a China Phase III trial of Arcatus® to treat uveitic macular edema, a cause of blindness. The candidate is designed to deliver therapies through the suprachoroidal space in the back of the eye, which is expected to allow the active ingredients to work longer with less harm to the rest of the eye. In 2020, Arctic Vision in-licensed rights to the drug, known as Xipere®, from Clearside Biomedical, a US company, for $35.5 million. The drug is administered using Clearside’s SCS Microinjector™ device. More details....

Stock Symbol: (NSDQ: CLSD)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital